Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the head's up. We know that Illiad Research values POTN at well above .45/share. It is just a matter of time until the CEO gets everything in place for uplisting, increase in sales and increase in share price.
"Was at a hemp show this past weekend in Portland and talked to some companies that follow the hemp show scene. All said Diamond is the biggest when it comes to the big shows. They make it known they are at a show. Always the busiest booth at the shows. Tells you something when everyone else with companies in this industry knows who the big players are. Also talked with a financial hemp investment company at the show and even they said they were heavily invested in POTN.
Let's hope the PR tomorrow puts Southridge and Vacarro to bed for good.
You mean REVERSAL from .08 to .80 I assume.
If this results in a PR that all debt has been settled with Vaccaro this stock will fly. IMO this is what has been holding it back. With the Southridge lawsuit win and uncertainty over Vaccaro's shares behind us, signs will be removed from OTC website and uplist will occur.
When we get the big PR about debt resolution (Vaccaro), the share price will soar - like Tilray today. Vaccaro - make a deal!!! Make yourself and POTN shareholders worth a lot more money.
https://finance.yahoo.com/news/otc-markets-group-launches-otcqx-110000322.html
POTN can apsire to this index someday
I agree that POTN is very undervalued for an early stage company with 25 million in revenues. They are a dominant player in US CBD retail, and soon will swing to higher earnings as new products are placed into the market and get traction, sales increase and costs go down now that they have a trained sales force.
We need a strong positive swing in sentiment for this sector, like late last year. It will take getting past trade wars (and the Fed lowering rates will also be a huge help) and some good Q2 revs IMO. Q1 was flat for pretty much the whole sector.
This entire sector is very cyclical. You can make money if you buy low, like now, and sell when it flies up- which I think will be Q2 for the next big upturn. If you don't have faith that the high revenue stocks will eventually corner the market and become profitable, why not move on to something else instead of sitting on this board and complaining?
Absolutely.
POTN has methodically reached each milestone announced, most recently audited earnings for 2 years and SEC registration. Next up is uplisting, it always takes longer than expected and the CEO is no doubt working hard behind the scenes to make this happen. Q2 earnings will jump up IMO for the sector and buying will start again for all high potential high revenue stocks. The biggest uncertainty I believe, is the high level of uncertainty in the markets due to the daily trade war onslaught.
These are usually pre-arranged trades when you see a huge sell immediately followed by a huge buy of the same number of shares and no change in share price. My guess is a stake holder is getting in.
Agree. The CEO will need to be more transparent about share structure in the near future for uplisting to occur. I am wondering if he is waiting for the August resolution of the law suit or some type of negotiation with the early stage investor Vacarro.
We can close at .11 today with a good power hour.
Thinking about what could have persuaded Illiad Research to value POTN above .45/share during Q1... It wasn't Q1 revs and certainly not earnings, nor the possibility of SEC reporting or uplisting since both were too far into the future and high risk several months ago. My best guess is that POTN has inked a distribution deal with a national pharmacy chain like CVS - and their edible CBD products will be available as soon as the FDA clarifies their rulings.
Anybody have other ideas?
And traded 4 million in the first 8 minutes.
Up 10% after hitting .12 on the open is a bad thing?
Hagen is telling us to expect a big jump in Q2 revenues, wow look at the volume! This stock will fly with the upcoming catalysts.
2019 WILL BE THE YEAR OF CBD, good article:
https://nicinvestors.com/2019/06/04/what-you-need-to-know-about-the-fda-and-cbd/
I hope to see a big turnaround in sentiment for the CBD/MJ sectors soon, most are very oversold.
Morgan Stanley says our economy is in a downturn and risky assets will be hit first (like cannabis sector). POTN is holding up very well today, uplist imminent IMO.
"Nevertheless, the gloomy backdrop for global trade along with elevated equity and corporate bond valuations means investors shouldn’t take any chances and start to cut down their holdings of risky assets now, said Tang.
The REAL information regarding the FDA hearing:
https://www.marketwatch.com/story/cannabis-stocks-fall-after-fda-hearing-on-cbd-finds-conflicting-views-of-substance-2019-06-03
"At CIBC, analysts noted that a World Health Organization report found CBD to be safe and nonaddictive, although they acknowledged that most experts fret there is still insufficient data from trials. What is clear is the strong demand for CBD, they wrote in a note to clients, citing a speaker at the hearing from Consumer Reports, who said that about 65 million Americans have tried CBD and 63% found it effective.
“Furthermore, more Americans’ primary concern was pricing rather than safety,” said the note.
Good thing POTN has a large loyal customer base for their CBD gummies, Charlotte's Web (whose stock fell 10% Friday), is entering the market belatedly- today's news:
https://finance.yahoo.com/news/charlottes-announces-hemp-extract-cbd-131500394.html
"The market for gummy vitamins for wellness is a global phenomenon, forecasted to rise at a CAGR of 5.2% between 2017 and 2025 according to Transparency Market Research and reaching US$4.17 billion by 2025. CBD gummies specifically have gained significant popularity lately as more people learn about CBD and its potential health benefits. In 2018 "CBD gummies" ranked as the third most searched term in the food category on Google"
Let's not forget that POTN can get loans now for favorable terms like 0.45/share, enabling large increases in production and better product availability, and fewer sold out products.
The whole sector, including top sellers like Charlottes Web, had a lower Q1. POTN CEO Hagen expects 2019 to be much higher than 2018, count on it.
The FDA meeting did not mention individual companies, provide a link to your claim. I am a pharmaceutical and botanical researcher. Diamond has been providing analytical data for each product on their web site for years. Your claim seems fishy to me.
Reality check. POTN had $25 million in revs LAST year in an extreme growth industry, market cap is barely 3x revs, is uplisting this month away from crazy manipulation, and Illiad research did DD valuing its share price at over .45, your money will be worth 5x within months if invested here.
POTN is looking great today compared to the rest of the sector- and in spite of the huge daily market downdrafts. If it wasn't for the severe uncertainty in the markets due to crazy trade wars, the share price would be MUCH higher IMO.
"We had an incredible year in 2018 when we earned over $25 million in revenue, a 78% year-over-year increase, and we expect to handily beat those figures in 2019" said CEO Hagen.
Uplisting will likely occur in June, and the second quarter will see higher revenues for the whole sector. POTN is the most undervalued CBD stock with the highest potential IMO. I expect more big announcements soon.
We also expected SEC registration/reporting and uplisting by last fall. Everything takes longer than we would like in the business and legal worlds, unfortunate reality.
14 million is a lot when you have no revenue.
POTN will be out of the "pinks" in weeks.
Highly unlikely, this stock is very undervalued here. It actually HAS high revenues, unlike many others on OTC that are dreaming about future revs.
Good news on the lawsuit also if this is accurate- from the yahoo board:
Plaintiff's (southridge partners) motion for partial summary judgement (PL41) was denied. Def motion (potn) for summary of judgement (DEF#51) still pending. Both sides have agreed to a settlement conference scheduled on August 13th at 1pm
Dilution is no longer necessary now that banking laws have changed. Uplisting will bring in big investors also. This is the tip of the iceberg for POTN - at the forefront of CBD retail.
We have 2 hrs audited earnings, revenues will be well over 30 million this year, uplisting to OTCQB within a few weeks, small market cap- very undervalued and great potential IMO. The wait is almost over.
Illiad also invested in CVSI, and is a group in Chicago.
$.5 to $1 valuation by Illiad Research
Nothing to do but wait for the disclosure that is going to take the share price to .45 and higher.
You forgot the huge revenues and low price to revenue ratio- it is currently a value stock at these levels. I expect a bump in revenues due to increasing the supply chain with CBD purchases from VPOR, which will allow supply to meet demand and decrease "sold out" products. When uplisted, big investors will buy shares and stabilize the share price.
POTN is still very undervalued, Q1 was slow for the sector and Q2 will be much higher with a jump in earnings IMO.